- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04161378
Impact of Cardiac Rehabilitation Programs on Left Ventricular Remodeling After Acute Myocardial Infarction - the REHAB Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
While the role of early mobilization in the immediate postinfarction period has been well demonstrated, little is known in present about the link between early mobilization and reduction of systemic inflammation. At the same time, the impact of early mobilization on regression of left ventricular remodeling has not been elucidated so far.
The study will be a single-center, observational, non-randomized study, which will be carried out in the Center of Advanced Research in Multimodal Cardiac Imaging Cardiomed, including 100 patients with AMI, presenting with either ST-segment elevation acute myocardial infarction (STEMI) or non-ST-segment elevation AMI (NSTEMI). According to the moment of mobilization after AMI patients will be distributed in two groups: group 1 - patients with early mobilization (<2 days after the onset of symptoms), and group 2 - subjects with delayed mobilization after AMI (>2 days after the onset of symptoms).
Each patient will be evaluated in terms of systemic inflammatory status in the immediate postinfarction phase, at baseline and at 7 days after AMI. In order to assess ventricular function and remodeling, extent of myocardial scar and transmurality index, late gadolinium enhancement CMR will be performed for each patient.
The study will be conducted over a period of 2 years, in which patients will be examined at baseline, and will be followed-up for 1 year for occurrence of MACE.
All patients will sign an informed written consent prior to study enrollment.
Study objectives:
Primary: to evaluate the impact of early mobilization after AMI on the ventricular remodeling in the post-infarction period, as assessed by CMR imaging. Secondary: to assess the rate of in-hospital mortality and the rate of repeated revascularization or MACE (including cardiovascular death or stroke) in patients with early mobilization as compared to those with delayed mobilization, and the effect of early mobilization on systemic inflammation in the immediate postinfarction phase.
Study Timeline:
- Baseline (day 0):
- Achieve written informed consent form all patients
- Check all inclusion/exclusion criteria
- Record demographic information, medical records, cardiovascular risk factors
- Perform and record physical examination and 12-lead ECG
- Laboratory analysis (CBC, routine biochemistry, inflammatory biomarkers, acute adhesion molecules)
- Transthoracic echocardiography / speckle tracking
- Visit 1 (day 7 / discharge from the hospital):
- hs-CRP assessment
- Visit 2 (month 1):
- LGE-CMR (myocardial fibrosis/scar, infarct size, transmurality, remodeling)
- Visit 3,4,5 (month 3,6,9):
- Record results of physical exam, medical records, ECG
- Transthoracic echocardiography / speckle tracking
- Final study visit (month 12):
- Record results of physical exam, medical records, ECG
- Transthoracic echocardiography / speckle tracking
- End-point assessment
Study procedures:
- Medical records, physical exam;
- Laboratory analysis (complete blood count, biochemistry, serum levels of hs-CRP, MMPs, IL6, NT-pro-BNP);
- Electrocardiography
- Transthoracic echocardiography for assessment of left ventricular systolic and diastolic performance, speckle tracking echocardiography, Dobutamine viability test
- Late gadolinium enhancement CMR for evaluation of ventricular function and remodeling, extent of myocardial scar and transmurality index.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Targu Mures, Romania, 540124
- Cardio Med Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with AMI in the last 12 hours;
- Successful revascularization of the culprit artery within the first 12 hours after the onset of symptoms in STEMI or within first 48 hours in NSTEMI (according to the risk class);
- Signed written informed consent.
Exclusion Criteria:
- Patient refusal;
- Any condition that would contraindicate CMR examination;
- Women during pregnancy or lactation period;
- Women able to procreate without any contraceptive usage;
- Chronic kidney disease (glomerular filtration rate <60ml/min/1.73m2) or acute renal injury that requires hemodialysis;
- Any type of neoplasia documented in the last 3 years before randomization;
- Expectation of life < 1 year.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
RHB-SG 01
Patients with early mobilization (< 2 days after the onset of symptoms)
|
|
RHB-SG 02
Patients with delayed mobilization after AMI (>2 days after the onset of symptoms)
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventricular remodeling in the post-infarction period
Time Frame: Month 1
|
LGE-CMR evaluation for myocardial fibrosis/scar, infarct size, transmurality, remodeling assessment.
|
Month 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major adverse cardiovascular events
Time Frame: 12 months
|
Rate of MACE at follow-up
|
12 months
|
Systemic inflammation in the immediate postinfarction phase
Time Frame: Day 7
|
Inflammatory status evaluation via hs-CRP assessment at baseline and at 7 days from the acute event.
|
Day 7
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CM0121-REHAB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
Deutsches Herzzentrum MuenchenDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)CompletedAcute Coronary Syndrome (ACS)Germany, Italy
-
Northwestern UniversityTerminatedACS - Acute Coronary SyndromeUnited States
Clinical Trials on Cardiac imaging
-
Ottawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR); The Finnish Funding Agency for...CompletedCoronary Artery Disease | Heart Failure | Ischemic CardiomyopathyCanada, Finland, United States, Argentina, Brazil
-
Johann Wolfgang Goethe University HospitalJohannes Gutenberg University Mainz; University Hospital Ulm; Kerckhoff KlinikActive, not recruitingMyocardial Fibrosis | Heart Failure | Myocarditis | Vascular InflammationGermany
-
University Hospital Plymouth NHS TrustCompleted
-
RWTH Aachen UniversityHeidelberg UniversityCompletedAcute Myocardial InfarctionGermany
-
Ohio State UniversityCompleted
-
Cardio Med Medical CenterUniversity of Targu Mures, Romania; University Hospital of Targu Mures, RomaniaCompletedPeriodontal Diseases | Atherosclerosis | Acute Coronary Syndrome | Coronary Stenosis | Acute Myocardial Infarction | Unstable Angina | Atheromatous Plaques | Non-ST Elevation Myocardial InfarctionRomania
-
Cardio Med Medical CenterCompletedAtherosclerosis | Acute Coronary Syndrome | Coronary Stenosis | Acute Myocardial Infarction | Unstable Angina | Atheromatous Plaques | Non-ST Elevation Myocardial InfarctionRomania
-
Turkish Ministry of Health Izmir Teaching HospitalUnknownAcute Coronary Syndrome | Clinical Decision Support SystemTurkey
-
Ohio State UniversityCompletedCoronary Artery DiseaseUnited States
-
University of Colorado, DenverActive, not recruitingCancer | Cardiotoxicity | Radiation TreatmentUnited States